ToxNav®
Prediction of toxicity to 5-FU/capecitabine chemotherapy
CommercialActive
Key Facts
Indication
Prediction of toxicity to 5-FU/capecitabine chemotherapy
Phase
Commercial
Status
Active
Company
About Oxford Cancer Biomarkers
Oxford Cancer Biomarkers is a private, commercial-stage diagnostics company leveraging biomarker and AI technology to personalize cancer care, starting with colorectal cancer. Its lead commercial product, ToxNav®, predicts patient risk of severe toxicity from common chemotherapies (5-FU/capecitabine), while its prognostic test, OncoProg, uses AI and digital pathology to stratify relapse risk. Founded by academic oncologists, the company is expanding through U.S. and European partnerships and has a pipeline aimed at broadening its technology to other cancers.
View full company profile